BLAINTRAVENOUSSOLUTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Mechanism of Action
Pharmacologic Class:
Antigen Neutralization
Clinical Trials (5)
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Started Dec 2025
360 enrolled
HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions+1 more
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Started Oct 2023
30 enrolled
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Started Jun 2021
71 enrolled
Pediatric Acute-Onset Neuropsychiatric Syndrome
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Started Dec 2020
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Started Oct 2020
247 enrolled
Chronic Lymphocytic LeukemiaHypogammaglobulinemia